Join Deborah W. Brooks, MJFF Co-Founder, and James Leverenz, MD, of the University of Washington for a community discussion on Parkinson’s disease research.

Join MJFF Co-Founder Deborah W. Brooks and a panel of experts in the field for an MJFF Research Roundtable for a presentation on current Parkinson's research and expert Q&A.

The Michael J. Fox Foundation has committed up to $12 million in 2011 funding for prioritized research toward transformative treatments and a cure for Parkinson’s disease.

Philanthropist Lily Safra's gift will support the Parkinson’s Progression Markers Initiative (PPMI). Mrs. Safra’s commitment will help galvanize the search for a biomarker of Parkinson’s disease progression.

The Wall Street Journal's "Donor of the Day" column features Mrs. Lily Safra's $2.5 million gift to MJFF to support the Parkinson's Progression Markers Initiative.

The Foundation’s Target Validation initiative, one of MJFF’s Edmond J. Safra Core Programs for PD Research, provides intellectual and financial resources to validation studies, helping to advance potential PD drug targets toward clinical trials and Parkinson’s patients.

Join an educational webinar on July 14, 2010 to learn more about participating in Parkinson's clinical trials.

The Michael J. Fox Foundation for Parkinson's Research thanks EHE International for helping raise awareness through an interactive display window in the heart of Rockefeller Center.

The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development.

Funded investigations aim to push forward approaches that could slow or stop progression of the disease, alleviate symptoms or refine existing therapies.

PD Online Research is a Web-based community of Parkinson's scientists, clinicians, health care providers, drug developers and funders who exchange ideas and information online in an effort to speed research progress. 

Sergey Brin, co-founder of Google, discusses his investments in PD research to "really move the needle". Brin is an "active and enthusiastic investor" in The Michael J. Fox Foundation.

The awards support two promising studies of neurotrophic factor therapies to help speed this avenue of research toward better treatments for people living with PD.

Hosted by MJFF and the New York Academy of Sciences, the PD Therapeutics Conference is the only major scientific symposium exclusively focused on speeding PD therapeutic development. 

"A Sunny Thing Happened on the Way to Cure Parkinson's," held on May 26th in Beverly Hills, featured a special musical performance by Joan Jett & the Blackhearts and comedy by Greg Behrendt.

Contributions made to The Michael J. Fox Foundation for Parkinson's Research support our organization's research efforts and are not used to support any political candidate or campaign.

There is a critical need for clinical trial participants — including people with Parkinson’s and healthy individuals. Learn about SURE-PD and STEADY PD, two promising trials currently in need of volunteers.

Join MJFF Co-Founder Deborah W. Brooks, Associate Director of Research Programs Brian Fiske, PhD, and members of the MJFF Scientific Advisory Board for a presentation on current Parkinson's research and expert Q&A.

Denny’s events kick off in New York to support Parkinson’s disease research

Join Deborah W. Brooks, MJFF Co-Founder, and Joseph Jankovic, MD, of Baylor College of Medicine for a community discussion on Parkinson’s disease research.

The funded projects complement the Foundation’s annually occurring Pipeline Programs and Critical Challenges in Parkinson’s Disease initiatives, which aim to accelerate PD therapeutic development.

The groundbreaking, $40 million, five-year observational clinical study seeks to identify biomarkers of Parkinson’s disease.

As part of the health care reform bill, CAN will help speed urgently needed medical treatments to market. MJFF is one of 81 organizations that is now requesting funds to support CAN.

Join us for a community discussion on Parkinson’s disease research.

Together, Dick's Sporting Goods National Runners’ Month and Team Fox will inspire runners across the country this spring to raise awareness and funds to find a cure for Parkinson's disease.

MJFF is making antibodies available to Parkinson's researchers around the world at no cost.

Join MJFF CEO Katie Hood and scientists from The Institute for Neurodegenerative Disorders for a community discussion on Parkinson’s disease research.

Join MJFF Co-Founder Deborah W. Brooks and The Parkinson's Institute Scientific Director and CEO J. William Langston, MD, for a community discussion on Parkinson’s disease research.

The LRRK2 Biology Consortium, funded by MJFF to advance understanding of the LRRK2 gene, is profiled in the March edition of Nature Medicine.

Nature Medicine discusses the latest technology for creating improved pre-clinical research models, including models funded by MJFF.

Karolinska awards honorary doctorates to people who have not earned a PhD through formal academic achievements, but who have benefited research through other means.

Two Challenges aim to streamline efforts focused on genetic targets alpha-synuclein and LRRK2. The third will drive collaborations that maximize the resources of the Brain & Body Donation Program at the Arizona Parkinson’s Disease Consortium.

Researchers will evaluate the disease-modifying potential of transdermal nicotine using standard skin patches of the type used by millions of smokers as a quitting aid.

Using a multipronged approach that includes collaboration between the research teams, the funded projects will help advance understanding of the LRRK2 gene.

Ex-NBAer Brian Grant's friendship with Michael J. Fox -- perhaps one of the most famous people living with Parkinson's -- has provided Grant with a compass, some sense of direction of what to do with his new life.

Join MJFF CEO Katie Hood, VP of Research Programs Todd Sherer, PhD, and three leading PD researchers for a presentation on current Parkinson's research and expert Q&A in Charlotte on Tuesday evening, February 23.

Strategic investment in new research technologies and tools is critical to attaining transformative new treatments that will make a tangible impact on patients’ lives.

The discovery of PD biomarkers, physiological characteristics that can be objectively measured and evaluated by researchers, are critical to PD drug development. 

Three teams will focus on inflammation and oxidative stress, two will target alpha-synuclein, and one will investigate HDACs, a family of enzymes shown to enhance expression of potential protective factors in preclinical PD models.